In the context of other genetic backgrounds, the L169P variant could possibly synergize with other oncogenic gene mutation(s), such as BAP1 and p53 uncovered in the highly aggressive and metastatic case of ccRCC [5], to drive tumorigenesis. Here, TP53 is linked to nonpapillary renal cell carcinoma.